QUARTERLY FINANCIAL INFORMATION AT SEPTEMBER 30TH, 2012
Longjumeau, October 16 th, 2012
Net sales up 7% at September 30th, 2012
(in thousands of euros) | 2011 | 2012 | % change |
First Quarter | 44,053 | 42,728 | - 3.0% |
including Pharmaceutical Synthesis | 27,147 | 25,454 | - 6.2% |
including Fine Speciality Chemicals | 16,906 | 17,274 | + 2.2% |
Second Quarter | 41,789 | 46,633 | + 11.6% |
including Pharmaceutical Synthesis | 26,457 | 29,910 | + 13.1% |
including Fine Speciality Chemicals | 15,332 | 16,723 | + 9.1% |
Third Quarter | 33,481 | 38,355 | + 14.6% |
including Pharmaceutical Synthesis | 19,530 | 23,298 | + 19.3% |
including Fine Speciality Chemicals | 13,951 | 15,057 | + 7.9% |
Total as of 30 September | 119,323 | 127,716 | + 7.0% |
including Pharmaceutical Synthesis | 73,134 | 78,662 | + 7.6% |
including Fine Speciality Chemicals | 46,189 | 49,054 | + 6.2% |
Following a stronger level of business during the third quarter of 2012 compared with the same period in 2011, the PCAS Group's net sales are up 7.0% at September 30th, 2012.
Pharmaceutical Synthesis
Net sales for the third quarter of 2012 came in 19.3% higher than the third quarter of 2011, reflecting the exceptionally concentrated volume of deliveries over this period in 2012.
Fine Specialty Chemicals
The Fine Specialty Chemicals business has continued to grow (+7.9% in the third quarter of 2012 versus the third quarter of 2011), despite the Fragrance business underperforming.
Compared with 2011, fourth-quarter net sales are expected to see significant growth on Pharmaceutical Synthesis, although without reaching the third quarter's exceptional rate of growth. For Fine Specialty Chemicals, the overall level of business looks set to be stable in the fourth quarter.
On the whole, net sales growth in 2012 is expected to closely follow the trend observed at the end of September 2012.
http://hugin.info/143512/R/1649601/531922.pdf
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: PCAS via Thomson Reuters ONE